

NatWest Markets N.V. Prospectus Supplement

The following Prospectus Supplement has been approved by the Netherlands Authority for the Financial Markets (*Autoriteit Financiële Markten*, "AFM") and is available for viewing:

Supplementary Prospectus to the NatWest Markets N.V. €5,000,000,000 Euro Medium-Term Note Programme dated 12 March 2025 (the "Supplementary Prospectus")

To view the full document, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/4320A_1-2025-3-12.pdf

A copy of the above Supplementary Prospectus has been submitted to the AFM and will shortly be available for inspection at:

<https://www.afm.nl/en/professionals/registers/meldingenregisters/goedgekeurde-prospectussen>.

For further information, please contact:

Vasilis Tsagris

NatWest Markets N.V. Treasurer

Tel: +31 20 464 2691

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Supplementary Prospectus (and the Base Prospectus to which it relates) may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus and the Supplementary Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus and the Supplementary Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

Legal Entity Identifier: X3CZP3CK64YBHON1LE12

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.